Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Majinyacin Farko An Yi Magani a Gwaji don Rhinosinusitis na Zamani na Bayan tiyata

Written by edita

Lyra Therapeutics, Inc. a yau ya sanar da cewa an yi wa mai haƙuri na farko magani a cikin Sashe na 1 / wanda ba a bazuwa ba na gwajin gwaji na Phase 2 BEACON na LYR-220 a cikin tsofaffi marasa lafiya tare da rhinosinusitis na kullum (CRS) waɗanda suka yi aikin tiyata na sinus. An ƙera LYR-220 musamman don isar da watanni shida na ci gaba da maganin hana kumburi a cikin tsari mai daidaituwa da daidaito zuwa ga hanyoyin sinonasal ga miliyoyin majinyatan CRS waɗanda ke ci gaba da buƙatar magani duk da tiyatar da aka yi a baya. Ana sa ran sakamako mafi girma daga Sashe na 1 na gwajin BEACON na mataki na 2 a kusa da ƙarshen shekara.      

Anders Cervin, MD, PhD, Farfesa Shugaban Otolaryngology a Cibiyar Nazarin Clinical, Royal Brisbane & Asibitin Mata ya ce "Muna da iyaka kuma sau da yawa marasa amfani da zaɓuɓɓukan magani don rage ci gaba, alamu masu nauyi a cikin marasa lafiya na CRS waɗanda aka yi wa tiyata a baya." Campus, Herston, a Queensland, Ostiraliya, da Babban Mai bincike a cikin binciken BEACON. "LYR-220 na iya wakiltar ci gaba mai ma'ana a cikin kulawa ga waɗannan marasa lafiya marasa lafiya, yawancin waɗanda ba su da zaɓin da aka yarda da maganin miyagun ƙwayoyi."

Gwajin 2 BEACON na Phase 220 nazari ne na rukuni-rukuni mai sarrafawa don kimanta aminci, haƙuri, pharmacokinetics, da inganci kwatankwacin ƙira biyu na matrix LYR-7500 (24µg MF) don sarrafawa, sama da tsawon sati 70, a cikin kusan 1 manya alamomi Ma'aikatan CRS waɗanda aka yi wa tiyatar sinus a baya. Sashe na 2 binciken bazuwar bazuwar, buɗaɗɗen lakabi yana kimanta yuwuwar sanyawa inganta tsarin, yayin da Sashe na 1 zai zama makafi mai haƙuri, 1: 1: 2 ƙima bazuwar ƙirar ƙira biyu tare da sarrafa sham. Kamfanin yana tsammanin kammala rajista don cikakken gwajin BEACON na Mataki na XNUMX a kusa da ƙarshen shekara.

"Wannan yana wakiltar wani muhimmin ci gaba ga Lyra yayin da muke ciyar da dan takararmu na biyu na CRS zuwa ci gaba a ƙarshen zamani, yana sanya mu zama farkon wanda zai ba da mafita ga cikakken nau'in marasa lafiya na CRS da likitocin ENT ke bi da su," in ji Maria Palasis, PhD. , Shugaba da Babban Jami'in Harkokin Kasuwancin Lyra Therapeutics. "Muna sa ran ci gaba da LYR-220 ta hanyar asibiti da kuma yin amfani da hanyar LYR-210, maganin binciken mu ga marasa lafiya na CRS tare da aikin tiyata-naive, a halin yanzu a cikin gwaji na Phase 3 (ENLIGHTEN I), don cikakkun bayanai na gaba. ”

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...